Navigation Links
Detailed studies reveal how key cancer-fighting protein is held in check
Date:5/15/2014

St. Jude Children's Research Hospital scientists have mapped the structural details of how p53 attaches to its regulatory protein, called BCL-xL, in the cell. The protein p53 is a key activator of the cell's protective machinery against genetic damage, such as the mutations that drive cancer cells' explosive growth.

The detailed understanding of how these two molecular puzzle pieces fit together will help scientists design drugs that release p53 in cancer cells, triggering their suicide, called apoptosis.

The findings appear in the current online journal Nature Structural & Molecular Biology. The research was led by co-corresponding authors Richard Kriwacki, Ph.D., a member of the St. Jude Structural Biology department, and Douglas Green, Ph.D., chair of the St. Jude Immunology department.

In guarding the cell against genetic damage, the p53 machinery functions both in the nucleus of the cell and in the cell's gel-like cytosol. When this machinery detects irreparable damage to the cell, p53 is unleashed to trigger apoptosis. In about half of all cancers, this machinery is rendered inoperable by mutation of p53, enabling cancer cells to proliferate despite their genetic malfunctions.

The protein BCL-xL is a central inhibitor of the p53 machinery, binding both p53 and other moleculescalled BH3 proteinsthat also drive apoptosis.

"The molecular details of how BCL-xl performs this dual inhibitory function were not understood," Kriwacki said. "Having those details has enabled us to determine exactly how BCL-xl can restrain or inhibit apoptosis through interactions with BH3-domain-containing proteins, as well as p53."

In their studies, the researchers used a structural analysis technique called NMR spectroscopy to map the 3-D structure of p53 binding to BCL-xL. Their experiments also revealed in detail how one region of the p53 protein, called the DNA-binding domain, serves double duty in the machinery. It enables p53 to attach to DNA in the cell's nucleus, helping the cell repair genetic damage. The same domain also acts as an attachment point for BCL-xL in the cytosol.

"The structural details that we report are novel," Kriwacki said. "And they provide the key insights for really dissecting the dual roles of BCL-xl in inhibiting apoptosis. Those roles are inhibiting the BH3-containing proteins on the one side, and p53 on the other. Also, through these studies we solidified the mechanistic understanding for how p53 functions in the cytosol, which complements its pro-apoptotic role in the nucleus."

The findings will help scientists design cancer-fighting drugs, Kriwacki said. In many cancers, p53 is prevented from triggering apoptosis by its attachment to BCL-xL. Drugs are currently being tested that bind to BCL-xL to free BH3 proteins to trigger apoptosis. However, Kriwacki said, new drugs could be developedbased on knowledge of p53's attachment to BCL-xLthat also block BCL-xL from binding p53.

"Our hypothesis is that many cancers have normal p53, but it is being tied up by BCL-xL," he said. "If it could be released, it could play its role in triggering apoptosis. A drug that could block both of BCL-xL's anti-apoptotic functions could potentially more profoundly induce apoptosis in cancer cells."

Kriwacki also said that the paper was significant because it emphasizes the importance of the role that p53 plays in the cytosol of the cell, in addition to its role in the nucleus; his further studies are seeking to map that molecular machinery in great detail.


'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital
Source:Eurekalert

Related medicine news :

1. Pill-sized device provides rapid, detailed imaging of esophageal lining
2. Revolutionary imaging software offers more detailed, clearer scans of heart conditions
3. Tennis Score Tracker 3.0 Now Available - The Most Advanced Tennis Scorekeeper for the iPhone, iPad, iPod touch, with Detailed Statistics, Live Scoring, 20+ New Features
4. TechReviews Publishes Latest Detailed Reviews for Best Electric Toothbrushes
5. Pastor of The House of Yahweh Publishes Detailed Article on Why Almost Total Destruction Is Near
6. Definitive Healthcare Expands Database Coverage With Detailed Research On Over 400+ Health Insurance Payors
7. Scientists capture most detailed picture yet of key AIDS protein
8. Flavor Your Life Discusses the Detailed Nutritional Value and Composition of Olive Oil
9. First targeted nanomedicine to enter human clinical studies
10. Joint-Replacement Failure Rate Higher for Smokers: Studies
11. IADR/AADR publish studies on severe early childhood caries - proposes new classification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... OK (PRWEB) , ... July 25, 2017 , ... ... proud to announce the launch of their partnership to provide the Pharmacist ... the first pharmacy-focused platform in the country with the ability to develop the ...
(Date:7/25/2017)... ... July 25, 2017 , ... Therachat ... will be exhibiting and providing demos of its smart journaling platform at the ... Center in Washington D.C. from August 3-6, 2017. , The APA Annual Convention ...
(Date:7/25/2017)... , ... July 25, 2017 , ... ... ATM provider in the United States, today announced its partnership with financial technology ... , The foundation of the solution lies within Hyosung’s superior ATMs, assisted ...
(Date:7/25/2017)... Jacksonville, Fla. (PRWEB) , ... July 25, 2017 , ... ... employee and father Ezra Clark is taking advantage of a new benefit for employees ... “It really means a lot that the company supports me and other employees as ...
(Date:7/25/2017)... TX (PRWEB) , ... July 25, 2017 , ... SignatureCare ... emergencies in the Austin, TX area 24 Hours a day. , The ... Austin, TX. , “We’ve been open four months now and things are running ...
Breaking Medicine News(10 mins):
(Date:7/25/2017)... and CAMBRIDGE, Massachusetts , July 25, 2017 ... repurposing drugs to treat rare nervous system diseases, has concluded ... develop and market the drug SOM0226 against transthyretin amyloidosis (ATTR). ... very promising results in a Phase 2 study conducted in ... office in the United States ...
(Date:7/24/2017)... July 24, 2017 IBM (NYSE: IBM ) ... Quadrant for Solid-State Arrays (SSA) for the fourth year in ... According to Gartner, "Vendors in the Leaders quadrant have the ... Vision. A vendor in the Leaders quadrant has the market ... the acceptance of new technologies. These vendors demonstrate a clear ...
(Date:7/21/2017)... EDMONTON, Alberta , July 21, 2017 /PRNewswire/ ... University of Alberta in Edmonton, Canada ... partner journal, Schizophrenia 1 , demonstrating that AI ... schizophrenia with 74% accuracy. This retrospective analysis also ... symptoms in schizophrenia patients with significant correlation, based ...
Breaking Medicine Technology: